JP2013539747A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013539747A5 JP2013539747A5 JP2013528294A JP2013528294A JP2013539747A5 JP 2013539747 A5 JP2013539747 A5 JP 2013539747A5 JP 2013528294 A JP2013528294 A JP 2013528294A JP 2013528294 A JP2013528294 A JP 2013528294A JP 2013539747 A5 JP2013539747 A5 JP 2013539747A5
- Authority
- JP
- Japan
- Prior art keywords
- cyano
- phenyl
- xanthine oxidoreductase
- oxidoreductase inhibitor
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims 74
- 229940122272 Oxidoreductase inhibitor Drugs 0.000 claims 43
- 108010091383 Xanthine dehydrogenase Proteins 0.000 claims 43
- 102000005773 Xanthine dehydrogenase Human genes 0.000 claims 43
- 108010093894 Xanthine oxidase Proteins 0.000 claims 43
- 239000002457 oxidoreductase inhibitor Substances 0.000 claims 43
- 229960000278 theophylline Drugs 0.000 claims 37
- 201000010099 disease Diseases 0.000 claims 33
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 33
- 201000005569 Gout Diseases 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 12
- FFDDWBJYRJGZQH-UHFFFAOYSA-N 2-[3-cyano-4-(2-hydroxy-2-methylpropoxy)phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid Chemical compound S1C(C(O)=O)=C(C)N=C1C1=CC=C(OCC(C)(C)O)C(C#N)=C1 FFDDWBJYRJGZQH-UHFFFAOYSA-N 0.000 claims 8
- FPODSLPQWIIKKI-UHFFFAOYSA-N 2-[3-cyano-4-(3-hydroxy-2-methylpropoxy)phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid Chemical compound C1=C(C#N)C(OCC(CO)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 FPODSLPQWIIKKI-UHFFFAOYSA-N 0.000 claims 8
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical group C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 claims 8
- 201000001431 Hyperuricemia Diseases 0.000 claims 7
- 206010020772 Hypertension Diseases 0.000 claims 6
- 206010029148 Nephrolithiasis Diseases 0.000 claims 6
- 208000017169 kidney disease Diseases 0.000 claims 6
- 206010006458 Bronchitis chronic Diseases 0.000 claims 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 5
- 206010014561 Emphysema Diseases 0.000 claims 5
- 208000001647 Renal Insufficiency Diseases 0.000 claims 5
- 208000007718 Stable Angina Diseases 0.000 claims 5
- 206010046337 Urate nephropathy Diseases 0.000 claims 5
- 230000001154 acute effect Effects 0.000 claims 5
- 208000008784 apnea Diseases 0.000 claims 5
- 206010003246 arthritis Diseases 0.000 claims 5
- 208000006673 asthma Diseases 0.000 claims 5
- 230000036471 bradycardia Effects 0.000 claims 5
- 208000006218 bradycardia Diseases 0.000 claims 5
- 206010006451 bronchitis Diseases 0.000 claims 5
- 208000007451 chronic bronchitis Diseases 0.000 claims 5
- 230000001684 chronic effect Effects 0.000 claims 5
- 201000006370 kidney failure Diseases 0.000 claims 5
- 230000000750 progressive effect Effects 0.000 claims 5
- ZJDGVDDELZNDRA-UHFFFAOYSA-N 2-(3-cyano-4-hydroxyphenyl)-4-methyl-1,3-thiazole-5-carboxylic acid Chemical compound S1C(C(O)=O)=C(C)N=C1C1=CC=C(O)C(C#N)=C1 ZJDGVDDELZNDRA-UHFFFAOYSA-N 0.000 claims 4
- -1 3- (2-methyl-4-pyridyl) -5-cyano-4-isobutoxyphenyl Chemical group 0.000 claims 4
- CCUJKCXSZIJMAO-UHFFFAOYSA-N C(#N)C=1C=C(C=CC1OCC(C)(C)C)N1N=CC(=C1)C(=O)O.C(=O)(O)C(COC1=C(C=C(C=C1)C=1SC(=C(N1)C)C(=O)O)C#N)C Chemical compound C(#N)C=1C=C(C=CC1OCC(C)(C)C)N1N=CC(=C1)C(=O)O.C(=O)(O)C(COC1=C(C=C(C=C1)C=1SC(=C(N1)C)C(=O)O)C#N)C CCUJKCXSZIJMAO-UHFFFAOYSA-N 0.000 claims 4
- 201000001509 acute urate nephropathy Diseases 0.000 claims 4
- 238000011260 co-administration Methods 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 208000026101 uric acid urolithiasis Diseases 0.000 claims 4
- 230000000977 initiatory effect Effects 0.000 claims 2
- 206010007027 Calculus urinary Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000012659 Joint disease Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 201000007094 prostatitis Diseases 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 208000008281 urolithiasis Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38148210P | 2010-09-10 | 2010-09-10 | |
| US61/381,482 | 2010-09-10 | ||
| PCT/US2011/050870 WO2012033941A1 (en) | 2010-09-10 | 2011-09-08 | Methods for concomitant treatment of theophylline and febuxostat |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013539747A JP2013539747A (ja) | 2013-10-28 |
| JP2013539747A5 true JP2013539747A5 (enExample) | 2014-10-23 |
| JP5978216B2 JP5978216B2 (ja) | 2016-08-24 |
Family
ID=44653592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013528294A Active JP5978216B2 (ja) | 2010-09-10 | 2011-09-08 | テオフィリンとフェブキソスタットの併用療法のための方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US9107912B2 (enExample) |
| EP (1) | EP2613780B1 (enExample) |
| JP (1) | JP5978216B2 (enExample) |
| KR (1) | KR101797936B1 (enExample) |
| CN (1) | CN103298466B (enExample) |
| AU (1) | AU2011299153B2 (enExample) |
| BR (1) | BR112013005792A8 (enExample) |
| CA (1) | CA2812034C (enExample) |
| ES (1) | ES2532210T3 (enExample) |
| RU (1) | RU2013109380A (enExample) |
| WO (1) | WO2012033941A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2607953A1 (en) * | 2005-05-09 | 2006-11-16 | Tap Pharmaceutical Products, Inc. | Methods for treating nephrolithiasis |
| WO2007019153A2 (en) * | 2005-08-03 | 2007-02-15 | Tap Pharmaceutical Products, Inc. | Methods for treating hypertension |
| US20090124623A1 (en) * | 2006-11-13 | 2009-05-14 | Christopher Lademacher | Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors |
| CA2669935A1 (en) * | 2006-11-13 | 2008-05-29 | Takeda Pharmaceuticals North America, Inc. | Methods for preserving renal function using xanthine oxidoreductase inhibitors |
| AU2008206231A1 (en) * | 2007-01-19 | 2008-07-24 | Takeda Pharmaceuticals U.S.A., Inc. | Methods for preventing or reducing the number of gout flares using xanthine oxidoreductase inhibitors and anti-inflammatory agents |
| US20100311756A1 (en) * | 2009-01-22 | 2010-12-09 | Takeda Pharmaceuticals North America, Inc. | Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof |
| CN103298466B (zh) | 2010-09-10 | 2015-11-25 | 武田制药美国有限公司 | 茶碱和非布索坦的联合治疗方法 |
| CN103862983B (zh) * | 2012-12-12 | 2016-12-21 | 石狮市冠鑫反光材料有限公司 | 3d立体画制作工艺 |
| ES2552706B1 (es) * | 2014-05-29 | 2016-09-13 | Universitat De Les Illes Balears | La teobromina y sus derivados para el tratamiento o prevenciónde la litiasis renal |
| KR102133290B1 (ko) * | 2018-10-23 | 2020-07-13 | 연세대학교 산학협력단 | 결핵의 예방 또는 치료용 조성물 |
| CN120271528B (zh) * | 2025-04-08 | 2025-08-22 | 中国食品药品检定研究院 | 一种非布司他与苦豆碱共无定型物及其制备方法和应用 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3079303A (en) | 1958-12-11 | 1963-02-26 | Smith Kline French Lab | Basic tablet granulation and process of using same |
| US4058614A (en) | 1973-12-04 | 1977-11-15 | Merck & Co., Inc. | Substituted imidazole compounds and therapeutic compositions therewith |
| US4296122A (en) | 1975-07-09 | 1981-10-20 | Merck & Co., Inc. | 2,3-Dihydro-6,7-disubstituted-5-(acyl)benzofuran-2-carboxylic acids |
| DE2707269A1 (de) | 1977-02-19 | 1978-08-24 | Hoechst Ag | Heterocyclische stickstoffverbindungen und verfahren zu ihrer herstellung |
| DE2707270A1 (de) | 1977-02-19 | 1978-08-24 | Hoechst Ag | Pyrazolo-diazepine und verfahren zu ihrer herstellung |
| DE2707268A1 (de) | 1977-02-19 | 1978-08-31 | Hoechst Ag | Indol-3-carbaldehyd-oxime und verfahren zu ihrer herstellung |
| DE2727802A1 (de) | 1977-06-21 | 1979-04-19 | Hoechst Ag | Sulfamoyl-arylketone und verfahren zu ihrer herstellung |
| JPS5936919B2 (ja) | 1978-10-14 | 1984-09-06 | 日本新薬株式会社 | インド−ル誘導体 |
| DE3112116A1 (de) | 1981-03-27 | 1982-11-04 | Mundipharma GmbH, 6250 Limburg | "arzneimittel" |
| US4510322A (en) | 1981-07-13 | 1985-04-09 | Merck & Co., Inc. | Indacrinone having enhanced uricosuric |
| DE3232922A1 (de) | 1982-09-04 | 1984-03-08 | Hoechst Ag, 6230 Frankfurt | Sulfamoylbenzophenon-derivate, verfahren zu ihrer herstellung, ihre verwendung sowie pharmazeutische praeparate auf basis dieser verbindungen |
| US4632930A (en) | 1984-11-30 | 1986-12-30 | E. I. Du Pont De Nemours And Company | Antihypertensive alkyl-arylimidazole, thiazole and oxazole derivatives |
| US5047246A (en) | 1988-09-09 | 1991-09-10 | Bristol-Myers Company | Direct compression cyclophosphamide tablet |
| JPH0366669A (ja) | 1989-08-03 | 1991-03-22 | Shionogi & Co Ltd | 複素環式化合物 |
| SG86971A1 (en) | 1990-11-30 | 2002-03-19 | Teijin Ltd | 2-arylthiazole derivatives and pharmaceutical composition thereof |
| ATE162075T1 (de) | 1991-09-09 | 1998-01-15 | Warner Lambert Co | Pharmazeutisches kombinationspräparat, das ein uricosurisches mittel und einen excitatorischen aminosäure-antagonisten enthält |
| US5358961A (en) | 1991-11-30 | 1994-10-25 | Jin Ro Limited | Pyrrolidine derivatives |
| JP2706037B2 (ja) | 1993-04-13 | 1998-01-28 | 帝人株式会社 | シアノ化合物およびその製造方法 |
| SE9301830D0 (sv) | 1993-05-28 | 1993-05-28 | Ab Astra | New compounds |
| JPH07242694A (ja) | 1994-02-28 | 1995-09-19 | Yamasa Shoyu Co Ltd | トリアゾロプリンヌクレオシド誘導体及び該誘導体を製造するのに有用な合成中間体 |
| US5514681A (en) | 1994-08-17 | 1996-05-07 | Virginia Tech Intellectual Properties, Inc. | Compositions and methods for controlling pest insects |
| US6037344A (en) | 1994-08-17 | 2000-03-14 | Virginia Tech Intellectual Properties, Inc. | Compositions and methods for controlling pest insects |
| US5770601A (en) | 1994-08-17 | 1998-06-23 | Virginia Tech Intellectual Properties, Inc. | Compositions and methods for controlling pest insects |
| AUPM835394A0 (en) | 1994-09-23 | 1994-10-13 | King, Michael G. Dr. | Method for controlling or eliminating the need to smoke tobacco, and for treating ailments which may lead to the said need |
| US5990118A (en) | 1995-02-21 | 1999-11-23 | Yamasa Corporation | Purine compounds and xanthine oxidase inhibitors |
| US6084147A (en) | 1995-03-17 | 2000-07-04 | Studsvik, Inc. | Pyrolytic decomposition of organic wastes |
| JP3194964B2 (ja) | 1995-04-07 | 2001-08-06 | 帝人株式会社 | 臓器または組織保護剤 |
| JPH1045773A (ja) | 1996-08-07 | 1998-02-17 | Daicel Chem Ind Ltd | リン含有化合物およびその製造方法 |
| ID21775A (id) | 1996-10-25 | 1999-07-22 | Yoshitomi Pharmaceutical | Senyawa-senyawa 1-fenilpirazol dan penggunaan farmasinya |
| US5965625A (en) | 1997-03-21 | 1999-10-12 | King; Michael Glenn | Compositions and methods for the control of smoking |
| JPH11140086A (ja) | 1997-11-07 | 1999-05-25 | Yamasa Shoyu Co Ltd | ４−置換−１Ｈ−６−オキソピラゾロ［３，４−ｄ］ピリミジン化合物及びキサンチンオキシダーゼ阻害剤 |
| AU1520699A (en) | 1997-11-07 | 1999-05-31 | Johns Hopkins University, The | Methods for treatment of disorders of cardiac contractility |
| BR9906539A (pt) | 1998-06-19 | 2000-08-15 | Teijin Ltd | Polimorfo de ácido 2-(3-ciano-4-isobutil-óxi-fenil)-4-metil-5-tiazol-carboxì lico, composto amorfo, processos para produção de um composto amorfo, para produção de cristal, a, b, c, d, g de ácido. 2-(3-ciano-4-isobutil-óxi-fenil)-4-metil-5-tiazol-carboxì lico, e, polimorfo |
| PL202799B1 (pl) | 1998-08-06 | 2009-07-31 | Mountain View Pharmaceuticals | Sposób izolowania urykazy w postaci tetramerycznej oraz wyizolowana tetrameryczna urykaza |
| GB9824310D0 (en) | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
| US6372246B1 (en) | 1998-12-16 | 2002-04-16 | Ortho-Mcneil Pharmaceutical, Inc. | Polyethylene glycol coating for electrostatic dry deposition of pharmaceuticals |
| US6281222B1 (en) | 1999-08-19 | 2001-08-28 | Inotek Corporation | Compositions and method for treatment of acetaminophen intoxication |
| ECSP993280A (es) | 1999-12-17 | 2001-07-27 | Polimorfos de acido 2- (3- ciano -4 -isobutiloxi fenil) -4 -metil -5-tiazol carboxilico y metodo de produccion de los mismos | |
| DE60137635D1 (de) | 2000-06-28 | 2009-03-26 | Merck & Co Inc | Verwendung von allopurinol zur behandlung von bluthochdruck |
| JP2002105067A (ja) | 2000-09-28 | 2002-04-10 | Teijin Ltd | ２−フェニルチアゾール誘導体、およびそれを有効成分とする医薬組成物 |
| ITMI20010206A1 (it) | 2001-02-02 | 2002-08-02 | Dompe Spa | Uso della metansolfonammide di (r)-ibuprofene e dei suoi sali non tossici per la preparazione di medicamenti per il trattamento e la prevenz |
| WO2002085380A1 (en) | 2001-04-18 | 2002-10-31 | Geltex Pharmaceuticals, Inc. | Method for treating gout and reducing serum uric acid |
| BR0209133A (pt) | 2001-04-18 | 2004-06-15 | Genzyme Corp | Método para tratar gota e para reduzir os nìveis de ácido úrico n0 sangue |
| DE60208815T2 (de) | 2001-10-12 | 2006-07-20 | Bayer Pharmaceuticals Corp., West Haven | Phenyl substituierte 5-gliedrige stickstoff enthaltende heterocyclen zur behandlung von fettleibigkeit |
| BRPI0212775B8 (pt) | 2002-01-28 | 2021-05-25 | Fuji Yakuhin Co Ltd | composto de 1,2,4-triazol e medicamento |
| ES2505690T3 (es) | 2002-03-28 | 2014-10-10 | Teijin Pharma Limited | Preparación sólida que contiene una forma única de cristal de un derivado de ácido tiazolcarboxílico |
| US20060040945A1 (en) | 2002-05-17 | 2006-02-23 | Merckle Gmbh | Annellated pyrrole compounds as proton pump inhibitors for treating ulcer |
| US7078423B2 (en) | 2002-07-18 | 2006-07-18 | Inotek Pharmaceuticals Corporation | 5-Aryltetrazole compounds, compositions thereof, and uses therefor |
| US20040122067A1 (en) | 2002-12-20 | 2004-06-24 | Lin Zhao | Treatment of chronic heart failure |
| US20040121004A1 (en) | 2002-12-20 | 2004-06-24 | Rajneesh Taneja | Dosage forms containing a PPI, NSAID, and buffer |
| US20040131676A1 (en) | 2002-12-20 | 2004-07-08 | Rajneesh Taneja | Dosage forms containing a PPI, NSAID, and buffer |
| US7674820B2 (en) | 2003-08-07 | 2010-03-09 | Cardiome Pharma Corp. | Ion channel modulating activity I |
| WO2006028342A1 (en) | 2004-09-06 | 2006-03-16 | Biosynergen, Inc. | A novel xanthine oxidase inhibitor and a pharmaceutical composition containing the same |
| CA2587558A1 (en) | 2004-11-19 | 2006-05-26 | Shiva Biomedical, Llc | Methods of treating erythropoietin-resistance |
| CA2607953A1 (en) | 2005-05-09 | 2006-11-16 | Tap Pharmaceutical Products, Inc. | Methods for treating nephrolithiasis |
| WO2007019153A2 (en) | 2005-08-03 | 2007-02-15 | Tap Pharmaceutical Products, Inc. | Methods for treating hypertension |
| JP2009516691A (ja) | 2005-11-21 | 2009-04-23 | タツプ・フアーマシユーテイカル・プロダクツ・インコーポレイテツド | Ｑｔ間隔延長およびこれに伴う疾病の治療 |
| CA2669935A1 (en) | 2006-11-13 | 2008-05-29 | Takeda Pharmaceuticals North America, Inc. | Methods for preserving renal function using xanthine oxidoreductase inhibitors |
| US20090124623A1 (en) | 2006-11-13 | 2009-05-14 | Christopher Lademacher | Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors |
| AU2008206231A1 (en) | 2007-01-19 | 2008-07-24 | Takeda Pharmaceuticals U.S.A., Inc. | Methods for preventing or reducing the number of gout flares using xanthine oxidoreductase inhibitors and anti-inflammatory agents |
| MX2007011927A (es) | 2007-09-26 | 2009-03-26 | World Trade Imp Export Wtie Ag | Composiciones farmaceuticas que comprenden la combinacion de un agente antiinflamatorio no esteroideo y un agente inhibidor de la xantino oxidasa utiles para el control y tratamiento de la gota, artritis gotosa y enfermedades relacionadas. |
| US20100311756A1 (en) | 2009-01-22 | 2010-12-09 | Takeda Pharmaceuticals North America, Inc. | Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof |
| JPWO2011162390A1 (ja) | 2010-06-25 | 2013-08-22 | 帝人ファーマ株式会社 | 徐放性高血圧および腎機能障害治療剤 |
| NZ605562A (en) | 2010-07-09 | 2013-11-29 | Teijin Pharma Ltd | Deuterated benzylbenzene derivatives and methods of use |
| CN103298466B (zh) | 2010-09-10 | 2015-11-25 | 武田制药美国有限公司 | 茶碱和非布索坦的联合治疗方法 |
-
2011
- 2011-09-08 CN CN201180054390.5A patent/CN103298466B/zh not_active Expired - Fee Related
- 2011-09-08 EP EP20110758053 patent/EP2613780B1/en not_active Revoked
- 2011-09-08 BR BR112013005792A patent/BR112013005792A8/pt not_active Application Discontinuation
- 2011-09-08 KR KR1020137009027A patent/KR101797936B1/ko not_active Expired - Fee Related
- 2011-09-08 US US13/227,828 patent/US9107912B2/en active Active
- 2011-09-08 CA CA2812034A patent/CA2812034C/en not_active Expired - Fee Related
- 2011-09-08 JP JP2013528294A patent/JP5978216B2/ja active Active
- 2011-09-08 RU RU2013109380/15A patent/RU2013109380A/ru unknown
- 2011-09-08 WO PCT/US2011/050870 patent/WO2012033941A1/en not_active Ceased
- 2011-09-08 AU AU2011299153A patent/AU2011299153B2/en not_active Ceased
- 2011-09-08 ES ES11758053.0T patent/ES2532210T3/es active Active
- 2011-10-27 US US13/282,659 patent/US20120065207A1/en not_active Abandoned
- 2011-11-14 US US13/295,696 patent/US8372872B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013539747A5 (enExample) | ||
| RU2013109380A (ru) | Способ сопутствующей терапии с применением теофиллина и фебуксостата | |
| Chaudhary et al. | Uric acid-key ingredient in the recipe for cardiorenal metabolic syndrome | |
| JP2010509372A5 (enExample) | ||
| JP4643760B2 (ja) | Ｄｐｐ−ｉｖ阻害薬と他の糖尿病治療薬との併用又は組み合せからなる医薬 | |
| JP2013531028A5 (enExample) | ||
| AU2013299625B2 (en) | Treatment of immune-related and inflammatory diseases | |
| TWI505827B (zh) | 治療高尿酸血症及與高尿酸血症有關之新陳代謝疾病之方法及組合物 | |
| JP2010515715A5 (enExample) | ||
| JP2015508749A5 (enExample) | ||
| JP2008513515A5 (enExample) | ||
| JP2014012726A5 (enExample) | ||
| JP2008513514A5 (enExample) | ||
| JP2015531774A5 (enExample) | ||
| JP2008515905A5 (enExample) | ||
| RU2009122505A (ru) | Способы сохранения функции почек с использованием ингибиторов ксантин оксидоредуктазы | |
| JP2009510043A5 (enExample) | ||
| RU2007110933A (ru) | Комбинация антагонистов рецептора эндотелина а и ингибиторов фосфодиэстеразы 5 и ее применение | |
| DK3027183T3 (en) | SELECTIVE AT2 RECEPTOR AGONISTS FOR USING CACKSY TREATMENT | |
| JP2014502979A5 (enExample) | ||
| HRP20170584T1 (hr) | Novi spojevi piridazinona i piridona | |
| RU2019111882A (ru) | Антагонисты trpv4 | |
| JP2011524896A5 (enExample) | ||
| JP2011519865A5 (enExample) | ||
| FI3562487T3 (fi) | Metalloentsyymi-inhibiittoriyhdisteitä |